Featured Image
Why is it important?
Common tertiary drug resources provide conflicting recommendations relating to the choice of prostanoid drug, dose, and duration of therapy in patients with Raynaud's Disease when more conservative treatments and pharmacotherapy options have failed. This review provides evidence-based guidance on the use of epoprostenol pharmacotherapy for the management of Raynaud's Disease.
Perspectives
Read the Original
This page is a summary of: Evidence for the Use of Epoprostenol to Treat Raynaud’s Phenomenon With or Without Digital Ulcers, Annals of Pharmacotherapy, July 2016, SAGE Publications,
DOI: 10.1177/1060028016660324.
You can read the full text:
Contributors
The following have contributed to this page